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(57) ABSTRACT 
Instruments, systems, implants, and methods are provided for 
performing Submucosal medical procedures in a desired area 
of the digestive tract using endoscopy. Instruments include a 
safe access needle injection instrument, a submucosal tunnel 
ing instrument, a Submucosal dissection instrument, and a 
mucosal resection device. A submucosal implant device for 
diagnosing and treating disorders of the body may be 
implanted. A passive Submucosal implant device may take the 
form of a drug delivery depot in which a therapeutic agent 
within the depot elutes from the depot according to a prede 
termined elution profile. An active Submucosal implant 
device may take the form of a drug delivery device that 
incorporates a self-contained diagnostic system to determine 
the appropriate delivery time and dosage of a therapeutic 
agent to be administered. 
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1. 
METHODS AND SYSTEMIS FOR 
SUBMUCOSAL MPLANTATION OF A 
DEVICE FOR DAGNOSIS AND TREATMENT 
WITH ATHERAPEUTICAGENT 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application is a divisional of U.S. Ser. No. 1 1/776,097, 
filed Jul. 11, 2007, now issued as U.S. Pat. No. 8,066,689, 
which is hereby incorporated by reference herein in its 
entirety. 
FIELD OF THE INVENTION 
The present invention relates to a safe access needle injec 
tion instrument, a submucosal tunneling instrument, a Sub 
mucosal dissection instrument, a Submucosal implant device 
a system and a method for performing Submucosal medical 
procedures in a desired area of the digestive tract using an 
endoscope. One aspect in particular relates to the implanta 
tion of a device in the submucosal layer of the digestive tract 
for diagnosing or treating disorders of the body. 
BACKGROUND OF THE INVENTION 
The field of gastrointestinal endoscopy has for many years 
focused on diagnostic and therapeutic techniques to observe, 
modify and remove tissues located in the digestive tract. 
General endoscopic procedural techniques such as visualiz 
ing, dilating, cutting and manipulating tissue have been 
accomplished using flexible devices such as endoscopes, bal 
loons, Snares and electroSurgical tools well known in the art. 
While many of these devices and techniques have been 
useful in identifying and removing some neoplastic lesions of 
the mucosal layer as well as providing access to general 
locations within the digestive tract for the placement of sub 
mucosal implants, there are some lesions and areas of the 
digestive tract which are extremely difficult to resect or 
access. For example, the enbloc removal of large flat mucosal 
lesions presents numerous problems for current endoscopic 
tools and techniques. In addition, to effectively diagnosis 
Some disorders (gastric motility, irritable bowel syndrome, 
chronic intestinal pseudo-obstruction, etc.) a biopsy of the 
muscular wall or the myenteric plexus may be necessary. 
Currently, access to these types of specimens requires full 
thickness biopsies which can be particularly difficult from an 
endoscopic approach requiring extremely skilled closure 
techniques. 
There have been Some advances in endoscopic techniques 
to resect flat lesions of the mucosal layer generally termed, 
Endoscopic Mucosal Resection (EMR). One of these EMR 
techniques, “lift and cut, involves the injection of saline or 
other biocompatible solution beneath the lesion in an attempt 
to raise the lesion thereby changing the geometry to make it 
Suitable for resection using conventional Snare devices. 
Modifications to this technique are disclosed in U.S. Pat. 
No. 5,651,788 in which a lesion is identified and an injection 
catheter is used to inject saline to elevate the lesion. A ligator 
is attached to the distal end of the endoscope and Suction is 
applied to the lesion to bring the tissue into the ligator. A 
ligator band is then applied to the tissue to form a banded 
mushroom-like polyp which is suitable for removal with an 
electroSurgical Snare. 
Alternatively U.S. Pat. No. 5,961,526 discloses a coaxial 
needle and severing Snare assembly in which a needle is used 













with saline. Once the lesion is elevated, the needle is retracted 
from the tissue and the snare is extended from the needle 
lumento Surround the lesion. The lesion is then aspirated into 
an aspiration cylinder adjacent the distal end of the endoscope 
and the Snare is cinched to sever the tissue surrounding the 
lesion. 
While EMR techniques have been shown to be effective in 
treating some flat neoplastic lesions there are limitations and 
complications associated with these techniques. A major 
limitation associated with this technique is the size of the 
lesion that can be resected. Generally, these EMR techniques 
are suitable only for resecting mucosal lesions which are less 
than 2 cm in diameter. While larger or irregular shaped lesions 
may be resected in a piecemeal fashion, this is undesirable 
since Small portions of the lesion may remain. Another limi 
tation of these techniques includes uncertainty of the area 
being resected. Once tissue has been Suctioned into a cap 
ligator or aspiration cylinder, the tissue is directly adjacent the 
visualization means of the endoscope obscuring the field of 
view. One complication associated with these EMR tech 
niques is in relation to the use of the needle injection system. 
Manipulating the injection catheter to position the needle 
through the mucosal layer into the Submucosal layer can 
ultimately result in puncturing the muscular wall of the diges 
tive tract which may lead to infection or peritonitis. Another 
complication associated with EMR techniques is damage to 
the underlying muscular layer. Saline and other non-viscous 
fluids used to elevate the lesion dissipate relatively quickly 
after injection into the Submucosal layer, Such that portions of 
the underlying muscular layer may be included in the Suc 
tioned tissue and inadvertently damaged when using the elec 
trosurgical tool for resection. 
In order to overcome some of the size, irregular shapes and 
visualization limitations associated with EMR techniques, a 
new procedure called Endoscopic Submucosal Dissection 
(ESD) has been developed. With this procedure the periphery 
of the target resection area, which includes the lesion, is 
marked. An injection catheter is used to deliver a viscous fluid 
within the Submucosal layer, which does not readily dissipate, 
throughout the target resection area. Once the target resection 
area has been elevated, an incision is made through the 
mucosal layer at the edge of the resection area using an 
electroSurgical needle knife. The physician uses the needle 
knife to cut the mucosal layer along the periphery of the target 
resection area. Once the boundary of the resection area has 
been cut, the physician then uses the needle knife to manually 
cut the Submucosal connective tissue binding the mucosal 
layer to the muscular wall. Once the physician has completed 
the Submucosal dissection, the mucosal layer is free to be 
removed in one piece. While this procedure allows the phy 
sician to resect large, irregular shaped lesions en bloc, it 
requires a high degree of skill on the part of the physician and 
is still Subject to the complications associated with needle 
perforations and muscular layer injury. 
In performing the ESD method of resecting a neoplastic 
lesion, as well as, performing a Submucosal medical proce 
dure it is apparent that dissecting the connective tissue of the 
Submucosal space is an important step in having a successful 
outcome. Numerous investigators have attempted to provide 
ways of dissecting the Submucosal connective tissue. 
In U.S. Pat. No. 6,098,629 a method of implanting a sub 
mucosal esophageal bulking device is disclosed. The patent 
further discloses the use of a blunt dissecting member to 
create a Submucosal pocket. In addition, the patent discloses 
the use of a balloon inserted into the submucosal layer to 
dissect the submucosal tissue when dilated to form a submu 
cosal pocket. 
US 8.491472 B2 
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In PCT Patent Application No. WO 02/089655, methods of 
implanting Submucosal gastric implants are disclosed. The 
application further discloses various configurations of 
mechanical and electroSurgical dissection instruments for 
dissecting the connective tissue of the Submucosal layer to 
form a submucosal pocket in which to place a gastric implant. 
Included in the description of mechanical dissection instru 
ments are various configurations of balloon dissection instru 
mentS. 
In U.S. Patent Application No. US2005/0149099, a sub 
mucosal dissection instrument, System and method are dis 
closed. The application further discloses an electroSurgical 
high frequency knife in combination with a submucosal dis 
section balloon. Included in the method are the steps of 
sequentially activating the high frequency knife to create a 
hole and advancing the balloon assembly into the hole with 
expansion of the balloon dissecting the connective tissue of 
the submucosal layer. These steps of the method are repeated 
until all of the connective tissue beneath the lesion is com 
pletely dissected. 
With most of the aforementioned disclosed submucosal 
dissection techniques the physician is required to initially 
advance a significant portion of a dissection instrument into 
the Submucosal layer while the connective tissue is generally 
intact. These techniques require that a pushing force be trans 
mitted to the tip of the instrument to dissect the submucosal 
connective tissue. During application of this pushing force 
there is a risk that the tip of the instrument may injure or 
perforate the muscular wall or the mucosal layer. 
In performing the disclosed method using the electroSur 
gical high frequency knife the initial hole through the 
mucosal layer may be visualized endocopically. Once the 
balloon assembly is advanced into the Submucosal incision 
hole and expanded to create a cavity, further advancement of 
the high frequency knife to form a second hole must be 
conducted without visualization. During the second hole for 
mation and Subsequent holes, without visual confirmation of 
the orientation of the high frequency knife there is a risk of 
perforating the muscular wall or mucosal layer. 
SUMMARY OF THE INVENTION 
In accordance with one aspect of the present invention 
there is provided a safe access needle injection instrument for 
use in a mammal. The safe access needle injection instrument 
includes an elongated flexible tubular member with proximal 
and distal ends and a lumen extending therethrough. A tissue 
holding member is positioned adjacent the distal end of the 
tubular member. A needle member having proximal and distal 
ends with a lumen extending therethrough is slidably posi 
tioned within the lumen of the tubular member. 
The tissue holding member is integrally formed with the 
tubular member and is in the form of a window member 
adapted to engage the mucosal tissue within the digestive 
tract. A seal plug is included within the lumen of the tubular 
member distal to the window member. When a vacuum 
source connected to the proximal end of the tubular member 
is activated the vacuum causes the mucosal tissue to be suc 
tioned within the window member of the tissue holding mem 
ber. 
The needle member is coaxially disposed within the lumen 
of the tubular member. The distal end of the needle member is 
operable from a first position proximal to the window mem 
berto a second position within the window member by axially 
advancing the needle member relative to the tubular member. 
Similarly, the distal end of the needle is operable from a 













proximal to the window member by axially retracting the 
needle member relative to the tubular member. When a 
vacuum is applied to the tubular member, the mucosal tissue 
is suctioned within the window member of the tissue holding 
member. The distal end of the needle member operated from 
its first position to the second position to thereby pierce the 
mucosal layer of the tissue and enter the Submucosal layer. 
In accordance with another aspect of the present invention 
there is provided a safe access needle injection instrument for 
use in a mammal. The safe access needle injection instrument 
includes an elongated flexible tubular sheath member with 
proximal and distalends and alumen extending therethrough. 
A tissue holding member is positioned adjacent the distal end 
of the tubular sheath member. A needle member having proxi 
mal and distal ends with a lumen extending therethrough is 
slidably positioned within the lumen of the tubular sheath 
member. 
The tissue holding member takes the form of a pair of 
operable jaws connected to the distal end of an elongate shaft 
member. The jaws are adapted to engage the mucosal tissue 
within the digestive tract. The elongate shaft member is slid 
ably disposed within the lumen of the tubular sheath member. 
The jaws are operable from an open configuration in which 
the jaws are biased outwardly when unconstrained, to a 
closed configuration in which the jaws approach each other 
when partially or fully constrained. When the tissue holding 
member is positioned adjacent the distal end of the tubular 
sheath member and the jaws are unconstrained, proximal 
movement of the elongate shaft member relative to the distal 
end of the tubular sheath, causes the jaws to be partially 
constrained and move from the open configuration to the 
closed configuration. 
The needle member is coaxially disposed within the lumen 
of the tubular member. The distal end of the needle member is 
operable from a first position proximal to the tissue holding 
memberjaws to a second position between the tissue holding 
member jaws, by axially advancing the needle member rela 
tive to the elongate shaft member. Similarly, the distal end of 
the needle is operable from a second position between the 
tissue holding memberjaws to a first position proximal to the 
tissue holding jaws by axially retracting the needle member 
relative to the elongate shaft member. When the jaws of the 
tissue holding member are positioned adjacent the mucosal 
tissue and are operated from an open to closed configuration, 
mucosal tissue is grasped and held between the jaws. The 
distal end of the needle member is then operated from the first 
position to the second position to thereby pierced the mucosal 
layer of the tissue and enter the Submucosal layer. 
In accordance with another aspect of the present invention, 
the needle member further includes a stop member positioned 
adjacent the distal end of the needle member. When the distal 
end of the needle member pierces the mucosal layer, the stop 
member engages the mucosal tissue to thereby limit the depth 
to which the needle penetrates through the mucosal layer. 
Once the stop member engages the mucosal tissue it may also 
seal around the needle such that fluid injected through the 
lumen of the needle into the submucosal layer does not exit 
the puncture site of the needle. 
In accordance with a further aspect of the present inven 
tion, a method is provided for operating a safe access needle 
instrument to create a safety bleb beneath the mucosal layer in 
the digestive tract of a mammal. The method includes the step 
of providing a safe access needle injection instrument. The 
safe access needle injection instrument having a tubular 
member, tissue holding member and a needle member slid 
ably disposed within the lumen of the tubular member. The 
method also includes the step of inserting the safe access 
US 8.491472 B2 
5 
needle injection instrument through a natural orifice into the 
digestive tract of a mammal. The method additionally 
includes the step operating the safe access needle injection 
instrument to engage mucosal tissue with the tissue holding 
member. The method also includes the step of piercing the 
mucosal layer with the needle member. The method further 
includes the step of injecting fluid through the needle member 
into the Submucosal layer. 
In accordance with another aspect of the present invention 
there is provided a safe access dissection system for use in a 
mammal. The safe access dissection system includes safe 
access needle injection instrument and an injectable dissec 
tion material. The injectable dissection material may take the 
form of a solution capable of dissolving the Submucosal con 
nective tissue. An example of this type of dissolving Solution 
is sodium 2-mercaptoethanesulfanate (MESNA). Additional 
Substances which may dissolve the Submucosal connective 
tissue include acids and enzymes Such as a peptase enzyme 
Solution, protease/collagenase, papain, chymotrypsin and 
acetylcycteine. The injectable dissection material may take 
the form of a non-pharmacological agent and provide a pure 
mechanical dissection of the Submucosal tissue. The 
mechanical injectable dissection material includes injectable 
Solutions which Solidify upon entering the Submucosal space, 
injectable semisolid gelatins, and injectable gelled micro 
spheres. Solutions which solidify after injection into the sub 
mucosal space may be thermosensitive polymer Solutions 
such as Pluronic 127. Additional injectable solidifying solu 
tions include monomer and polymer Solutions like hydrogels 
and cyanoacrylates which polymerize or crosslink upon con 
tact with tissue or added chemical agents. The semisolid 
gelatins and gelled microspheres may be formed of natural 
materials such as collagen and alginates or synthetic materi 
als like polyvinylalcohol (PVA), polyvinylpyrolidone (PVP) 
and acrylate polymers. 
In accordance with a further aspect of the present inven 
tion, a method is provided for operating a safe access dissec 
tion system to create a dissected safety bleb beneath the 
mucosal layer in the digestive tract of a mammal. The method 
includes the step of providing a safe access needle injection 
instrument and a dissecting material. The safe access needle 
injection instrument having a tubular member, tissue holding 
member and a needle member slidably disposed within the 
lumen of the tubular member. The method also includes the 
step of inserting the safe access needle injection instrument 
through a natural orifice into the digestive tract of a mammal. 
The method additionally includes the step operating the safe 
access needle injection instrument to engage mucosal tissue 
with the tissue holding member. The method also includes the 
step of piercing the mucosal layer with the needle member. 
The method further includes the step of injecting a dissecting 
material through the needle member into the submucosal 
layer where the Submucosal connective tissue is dissected, 
separating the mucosal layer from the muscular layer. The 
method may additionally include the step of removing the 
dissecting material from the mammal. 
In accordance with an aspect of the present invention, there 
is provided a Submucosal tunneling instrument. The Submu 
cosal tunneling instrument includes an elongate tubular mem 
ber having proximal and distal ends and a lumen extending 
therethrough and an elongate expandable member located at 
the distal end of the tubular member. The expandable member 
has proximal and distal ends wherein the proximal end of the 
expandable member is connected to the distal end of the 
tubular member. The expandable member is everted, such that 
the distal end of the expandable member is positioned within 













In accordance with an aspect of the present invention, there 
is provided a Submucosal tunneling instrument. The Submu 
cosal tunneling instrument includes an elongate tubular mem 
ber having proximal and distal ends and a lumen extending 
therethrough and an elongate expandable member located at 
the distal end of the tubular member. The expandable member 
has proximal and distal ends wherein the proximal end of the 
expandable member is connected to the distal end of the 
tubular member. The expandable member has a first spiral 
configuration, in which the distal end of the expandable mem 
ber is positioned within center of the rolled spiral shape, and 
a second extended configuration in which the proximal and 
distal ends of the expandable member generally take the form 
of a straight line shape. The expandable member is operable 
from a first spiral configuration to a second extended configu 
ration. The expandable member may also include a retaining 
member which maintains the shape of the expandable mem 
ber in its first spiral configuration during delivery and posi 
tioning of the Submucosal tunneling instrument. The retain 
ing member may take the form of a spiral shaped coil member 
affixed to the balloon. The spiral shaped coil member may be 
formed from metals or polymers which may be resilient or 
non-resilient. 
In accordance with yet another aspect of the present inven 
tion, the Submucosal tunneling instrument expandable mem 
ber takes the form of a balloon. The balloon may be of the 
compliant or non-compliant type generally known in the art. 
The balloon may be formed from biocompatible polymer 
types such as olefins, elastomers, thermoplastic elastomers, 
vinyls, polyamides, polyimides, polyesters, fluropolymers, 
copolymers and blends of any of the aforementioned. 
In accordance with still another aspect of the present inven 
tion, the expandable member takes the form of a tubular 
framework. The tubular framework may be constructed in 
different fashions such as a laser cut tube, braided and non 
braided mesh tubes. The tubular framework may be formed 
from polymers such as olefins, thermoplastic elastomers, 
vinyls, polyamides, polyimides, polyesters, fluropolymers, 
copolymers and blends of any of the aforementioned or met 
als such as stainless steel, nitinol and other biocompatible 
metallic alloys. 
In accordance with another aspect of the present invention 
the distal end of the expandable member is connected to the 
distal end of a tether member. The tether member is slidably 
disposed with the lumen of the tubular member and has a 
proximal end which is connected to a handle member. The 
tether membertakes the form of a flexible filament which may 
include a through lumen. The handle member may be used to 
adjust the length of the tether member to thereby control the 
length of the expandable member that is allowed to exit the 
lumen of the tubular member. 
In accordance with a further aspect of the present inven 
tion, a method is provided for operating a submucosal tun 
neling instrument to create a Submucosal tunnel beneath the 
mucosal layer in the digestive tract of a mammal. The method 
includes the step of creating a safety bleb beneath the mucosal 
layer. The method also includes the step of providing a Sub 
mucosal tunneling instrument. The Submucosal tunneling 
instrument has an elongate tubular member, and an everted 
expandable member located within the distal lumen of the 
tubular member. The method also includes the step of insert 
ing the Submucosal tunneling instrument through a natural 
orifice into the digestive tract of a mammal. The method 
additionally includes the step of forming an opening in the 
mucosal layer of the safety bleb. The method also includes the 
step of positioning the distal end of the Submucosal tunneling 
instrument through the formed opening in the mucosal layer. 
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The method further includes the step of operating the submu 
cosal tunneling instrument to thereby extend and expand the 
expandable member from the tubular member, thereby form 
inga Submucosal tunnel. The method then includes the step of 
removing the Submucosal tunneling instrument from the 
mammal. 
In accordance with another aspect of the present invention 
there is provided a submucosal tunneling system that includes 
a safe access needle injection instrument, a Submucosal tun 
neling instrument. The Submucosal tunneling system may be 
provided in the form of a kit. 
In accordance with still another aspect of the present inven 
tion there is provided a submucosal dissecting instrument. 
The Submucosal dissecting instrument includes an elongate 
tubular shaft member having proximal and distal ends and a 
lumen extending therethrough and an expandable member 
located at the distal end of the tubular shaft member. The 
Submucosal dissecting instrument may further include a 
marker or markers spaced apart known distances on the shaft 
of the tubular member to visually determine the length to 
which the distal end of the tubular member has been inserted 
into a Submucosal tunnel. The markers may additionally be 
made of radio-opaque material to thereby be visible under 
fluoroscopy. 
In accordance with still yet another aspect of the present 
invention, the expandable member of the submucosal dissect 
ing instrument takes the form of a balloon. The balloon may 
be of the compliant or non-compliant type generally known in 
the art. The balloon may beformed from biocompatible poly 
mer types such as olefins, elastomers, thermoplastic elas 
tomers, vinyls, polyamides, polyimides, polyesters, fluo 
ropolymers, copolymers and blends of any of the 
aforementioned. 
In accordance with a further aspect of the present inven 
tion, a method is provided for operating a submucosal dis 
secting instrument to create a large mucosal layer dissected 
area in the digestive tract of a mammal. The method includes 
the step of forming an elongate Submucosal tunnel beneath 
the mucosal layer. The method also includes the step of pro 
viding a submucosal dissecting instrument. The Submucosal 
dissecting instrument has an elongate tubular member, and an 
expandable member located at the distal end of the tubular 
member. The method also includes the step of inserting the 
Submucosal dissecting instrument through a natural orifice 
into the digestive tract of a mammal. The method additionally 
includes the step of positioning the distal end of the Submu 
cosal dissecting instrument through an opening formed in the 
mucosal layer into an elongate Submucosal tunnel. The 
method further includes the step of operating the Submucosal 
dissecting instrument to thereby dilate the expandable mem 
ber at the distal end of the tubular member, thereby forming a 
large mucosal layer dissected area. The method then includes 
the step of removing the Submucosal dissecting instrument 
from the mammal. 
In accordance with a further aspect of the present invention 
there is provided a Submucosal tunneling and dissecting 
instrument. The Submucosal tunneling and dissecting instru 
ment includes an elongate first tubular member having proxi 
mal and distal ends and a lumen extending therethrough and 
an elongate first expandable member located at the distal end 
of the first tubular member. The first expandable member has 
proximal and distal ends wherein the proximal end of the first 
expandable member is connected to the distal end of the first 
tubular member. The first expandable member is everted, 
such that the distal end of the first expandable member is 
positioned within the lumen of the first tubular member. The 














includes a second elongate tubular member having proximal 
and distal ends and a lumen extending therethrough and a 
second expandable member located at the distal end of the 
second tubular member. The elongate first tubular member is 
slidably disposed within the lumen of the elongate second 
tubular member, such that the distal end of the first tubular 
member may extend from the distal lumen of the second 
tubular member. 
In accordance with another aspect of the present invention 
there is provided a Submucosal dissection system that 
includes a safe access needle injection instrument, a Submu 
cosal tunneling instrument and a submucosal dissecting 
instrument. The Submucosal dissection system may be pro 
vided in the form of a kit. The submucosal dissection system 
may include a submucosal tunneling instrument and a Sub 
mucosal dissecting instrument which are integrally formed. 
In accordance with another aspect of the present invention 
there is provided a Submucosal implant device for diagnosing 
and treating disorders of the body. The Submucosal implant 
device may be a passive or active device. A passive Submu 
cosal implant device may take the form of a drug delivery 
depot in which a therapeutic agent within the depot elutes 
from the depot according to a predetermined elution profile. 
An active Submucosal implant device may take the form of a 
drug delivery device that incorporates a self contained diag 
nostic system to determine the appropriate delivery time and 
dosage of a therapeutic agent to be administered. The passive 
or active submucosal implant that takes the form of a drug 
delivery device may include a port positioned through the 
mucosal layer to allow endoscopic refilling of the drug deliv 
ery device with therapeutic agents. The Submucosal implant 
may include an anchor member in which to secure the implant 
to the muscular wall beneath the mucosal layer. 
In accordance with yet another aspect of the present inven 
tion there is provided a method for performing a submucosal 
medical procedure to deploy a submucosal implant device in 
the digestive tract of a mammal. The method includes the step 
of forming a submucosal tunnel beneath the mucosal layer in 
the digestive tract. The method also includes the step of 
providing a submucosal implant device. The method includes 
the step of inserting an endoscope through a mucosal opening 
into the area beneath the mucosal layer. The method also 
includes the step of positioning a submucosal implant device 
in the area beneath the mucosal layer. The method addition 
ally includes the step of releasing the Submucosal implant 
device beneath the mucosal layer. The method also addition 
ally includes the step of closing the mucosal opening. The 
method then includes the step of removing the endoscope 
from the mammal. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a side view of an endoscope of a submucosal 
medical procedure system according to an embodiment of the 
present invention. 
FIG. 2 is a side view of a safe access needle injection 
instrument according to an embodiment of a Submucosal 
medical procedure system of the present invention. 
FIG. 3 is a partial cross-sectional view of a safe access 
needle injection instrument according to an embodiment of a 
Submucosal medical procedure system of the present inven 
tion. 
FIG. 4 is a cross-sectional view taken along 4-4 of FIG. 3. 
FIG. 5A is a partial cross-sectional view showing a first 
position of the needle of a safe access needle injection instru 
ment according to an embodiment of a Submucosal medical 
procedure system of the present invention. 
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FIG. 5B is a partial cross-sectional view showing a second 
position of the needle of a safe access needle injection instru 
ment according to an embodiment of a submucosal medical 
procedure system of the present invention. 
FIG. 6A through 6E are cross-sectional views showing a 
method creating a submucosal bleb using the safe access 
needle injection instrument in accordance with an embodi 
ment of the present invention. 
FIGS. 7A through 7C are partial cross-sectional views of a 
safe access needle injection instrument according to another 
embodiment of a Submucosal medical procedure system of 
the present invention. 
FIGS. 8A through 8E are cross sectional views showing a 
method creating a submucosal bleb using the safe access 
needle injection instrument according to another embodi 
ment of present invention. 
FIG.9 is partial cross-sectional view of a safe access needle 
injection instrument according to another embodiment of the 
present invention. 
FIG. 10 is a perspective view of a safe access needle injec 
tion instrument according to another embodiment of the 
present invention. 
FIGS. 11A and 11B are cross-sectional views showing a 
method for dissecting a Submucosal layer according to an 
embodiment of the present invention. 
FIGS. 12A and 12B are cross-sectional views showing a 
method for dissecting a Submucosal layer according to 
another embodiment of the present invention. 
FIGS. 13A and 13B are cross-sectional views showing a 
method for dissecting a submucosal layer according to yet 
another embodiment of the present invention. 
FIG. 14 is a side view showing a Submucosal tunneling 
instrument of a submucosal medical procedure system in 
accordance with an embodiment of the present invention. 
FIGS. 15A and B are a cross-sectional views showing a 
Submucosal tunneling instrument of a submucosal medical 
procedure system in accordance with an embodiment of the 
present invention. 
FIGS. 16A through 16C are partial cross-sectional views 
showing a sequence of expanding the distal end of a Submu 
cosal tunneling instrument of a submucosal medical proce 
dure system in accordance with an embodiment of the present 
invention. 
FIG. 17 is a side view showing a variation of a submucosal 
tunneling instrument of a submucosal medical procedure sys 
tem in accordance with an embodiment of the present inven 
tion. 
FIG. 18 is a cross-sectional view showing a sequence of 
expanding the distal end of another variation a Submucosal 
tunneling instrument of a submucosal medical procedure sys 
tem in accordance with an embodiment of the present inven 
tion. 
FIGS. 19A through 19C are a side views showing another 
variation of a submucosal tunneling instrument of a submu 
cosal medical procedure system in accordance with an 
embodiment of the present invention. 
FIGS. 20A and 20B are perspective views showing a varia 
tion of the distal end of a Submucosal tunneling instrument of 
a Submucosal medical procedure system in accordance with 
an embodiment of the present invention. 
FIGS. 21A and 21B are perspective and cross sectional 
views of an area of tissue in the digestive tract having a 
submucosal salinebleb inaccordance with an embodiment of 
the present invention. 
FIGS. 22A and 22B are perspective and cross sectional 













Submucosal saline bleb in which an opening through the 
mucosal layer is made in accordance with an embodiment of 
the present invention. 
FIGS. 23A through 23D are perspective and cross sectional 
views showing a method of forming a submucosal tunnel 
using a submucosal tunneling instrument according to an 
embodiment of a Submucosal medical procedure system of 
the present invention. 
FIGS. 24A through 24D are perspective and cross sectional 
views showing a method of using a submucosal tunneling 
instrument according to an embodiment of a Submucosal 
medical procedure system of the present invention. 
FIGS. 25A through 25D are perspective and cross sectional 
views showing a method of using a submucosal dissection 
instrument in a Submucosal tunnel according to an embodi 
ment of a Submucosal medical procedure system of the 
present invention. 
FIG. 26 is a side view showing a combined submucosal 
tunneling and dissection instrument according to an embodi 
ment of a Submucosal medical procedure system of the 
present invention. 
FIG. 27 is a broken cross-sectional view of a combined 
Submucosal tunneling and dissection instrument according to 
an embodiment of a submucosal medical procedure system of 
the present invention. 
FIG. 28 is a cross-sectional view of the stomach showing a 
Submucosal implant according to an embodiment of a Sub 
mucosal medical procedure system of the present invention. 
FIGS. 29A through 29C are partial cross-sectional per 
spective views showing a method of positioning a Submu 
cosal implant according to an embodiment of a Submucosal 
medical procedure system of the present invention. 
FIGS. 30A through 30C are partial cross-sectional per 
spective views showing a method of positioning a Submu 
cosal implant according to another embodiment of a Submu 
cosal medical procedure system of the present invention. 
FIGS. 31A through 31F are partial cross-sectional perspec 
tive views showing a method of delivering a submucosal 
implant to a desired location within the digestive tract accord 
ing to yet another embodiment of a Submucosal medical 
procedure system of the present invention. 
DETAILED DESCRIPTION OF THE INVENTION 
Methods and devices for performing submucosal medical 
procedures in a desired area of the digestive tract using an 
endoscope are described. 
FIG. 1 illustrates an endoscope 2 of the type used in endo 
scopic procedures and suitable for use with embodiments of 
the present invention. The endoscope 2 has a working channel 
4 extending from a proximal portion of the endoscope to the 
distal end of the endoscope. The endoscope 2 also has an 
insertion section 6 which enters the body of a patient passing 
through a natural orifice Such as the mouth or rectum. The 
insertion section 6 is generally navigated to a position with 
the digestive tract when performing a submucosal medical 
procedure. Devices for use in performing Submucosal medi 
cal procedures are preferably delivered through working 
channel 4 of the endoscope 2; however devices may be deliv 
ered along side the insertion section 6 of the endoscope. 
FIG. 2 illustrates a safe access needle injection instrument 
10 which is used to aid the physician in obtaining access to the 
Submucosal layer to perform a Submucosal medical proce 
dure. The safe access needle injection instrument 10 includes 
a tubular shaft 12 having a distal end 13. The diameter of 
tubular shaft 12 is generally in the range 1 mm to 10 mm with 
a preferred range of 2.0 to 6.0 mm. Adjacent distal end 13, a 
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portion of the wall of tubular shaft 12 is removed to form 
window member 14. Alternatively, window member 14 can 
beformed with a cap element coupled to the distal end of the 
tubular shaft 12. Slidably disposed within the lumen of tubu 
lar shaft 12 is needle member 16. The proximal portion of 
tubular shaft includes vacuum port 18 which is capable of 
being coupled to a vacuum source Such as a Syringe or 
vacuum pump (not shown). Valve assembly 20 provides a 
releasable seal to tubular shaft 12. A handle assembly 21 is 
connected to tubular shaft 12 through connector tubing 22. 
The handle assembly 21 includes needle fluid port 24 and 
valve assembly 26 for injecting fluid through and sealing 
around the proximal portion of needle member 16. The proxi 
mal portion of needle member 16 is also connected to a needle 
slide member 28 positioned on handle body 30. The proximal 
movement of needle slide member 28 on handle body 30 
causes needle member 16 to move proximally within tubular 
shaft 12. Distance markers 32 are located on handle body 30 
to gauge the movement of needle member 16 within tubular 
shaft 12. 
As shown in FIGS.3 and 4, needle member 16 is positioned 
within lumen34 of tubular shaft 12. Located on the exterior of 
needle member 16 is stop member 36. The distal end 13 of 
tubular shaft 12 is closed with seal plug. 38. Also shown is 
needle member tip 40 and needle lumen 42. Needle lumen 42 
communicates needle tip 40 with needle fluid port 24 so that 
fluid injected through needleport 24 exits the lumen at needle 
tip 40. 
FIGS.5A and 5B, illustrate the actuation of needle member 
16. Needle member 16 is shown in detail with needle body 44 
connected to needle tip 40. Needle body 44 may be con 
structed of a separate material as shown or integrally formed 
with needle tip 40. Needle body 44 may be constructed from 
flexible tubing having good axial pushability. As shown in 
FIG. 5A, needle member 16 is in a first position in which 
needle tip 40 is located within lumen 34 proximal to window 
member 14. This is the preferred position for needle member 
16 when tubular shaft 12 is deployed within the body. Upon 
actuation, needle member 16 is moved to a second position in 
which needle tip 40 is positioned within window member 14. 
FIGS. 6A through 6E illustrate the operation of safe access 
needle injection instrument 10. Insertion section 6 of endo 
Scope 2 is passed through a natural orifice in a patient and 
positioned at a location in the digestive tract in which to 
perform a submucosal procedure. Safe access needle injec 
tion instrument 10 is deployed through the working channel 4 
of endoscope 2. As depicted in FIG. 6A the distal potion of 
safe access needle injection instrument 10 is positioned 
within the digestive tract adjacent mucosal layer 46. Beneath 
the mucosal layer are the Submucosal layer 48 and the mus 
cular layer 50. Window member 14 is oriented towards 
mucosal layer 46. Needle member 16 is located in a first 
position proximal to window member 14. A vacuum source is 
connected to vacuum port 18, which communicates with 
lumen 34, and the applied vacuum causes the tissue of the 
digestive tract to be suctioned into window member 14 as 
shown in FIG. 6B. The actuation of needle member 16 is 
shown in FIG. 6C as it is moved to its second position. Distal 
movement of needle member 16 causes needle tip 40 to move 
distally relative to tubular shaft 12 to thereby pierce the 
mucosal layer 46 and enter the submucosal layer 48 of the 
suctioned tissue. When needle member 16 is moved to its 
second position, stop member 36 engages the mucosal layer 
46. Stop member 36 prevents further distal movement of 
needle member 16 and provides a seal around needle tip 40. A 
pressurized fluid source is connected to needle fluid port 24 to 














submucosal layer 48. As fluid enters the submucosal layer 48 
from needle tip 40, as illustrated in FIG. 6D, the mucosal layer 
46 is elevated forming a submucosal bleb. The fluid used to 
create the bleb may be of any type suitable for the environ 
ment Such as solutions containing saline, hypertonic solu 
tions of Saline-epinephrine, sodium hyaluronate, poly-N- 
acetylglucosamine, sodium chondroitin Sulfate, chitosans or 
other biocompatible mucopolysaccharides. Although the 
mucosal layer 46 is elevated to form the submucosal bleb, the 
submucosal connective tissue 52 is only stretched and not 
broken by the infusion of fluid into submucosal layer 48. 
Once the needle member 16 is returned to its first position and 
the applied vacuum to lumen 34 is discontinued, the safe 
access needle injection instrument 10 may be removed from 
the safety bleb as illustrated in FIG. 6E. 
FIGS. 7A through 7C illustrate safe access needle injection 
instrument 60 which is another preferred embodiment of the 
present invention to aid the physician in obtaining access to 
the Submucosal space when performing a submucosal medi 
cal procedure. Safe access needle injection instrument 60 
includes a sheath member 62 having a proximal and distal end 
64 and a lumen 66 extending therethrough. Slidably disposed 
within lumen 66 of sheath member 62, there is an elongate 
shaft member 68 having a shaft lumen 69 and distal end 70. 
Located adjacent to distal end 70 of elongated shaft member 
68 is a pair of jaw members 72. Jaw members 72 may be 
formed from the wall of elongated shaft member 68. Prefer 
ably the jaw members 72 are formed of a resilient material 
and biased outwardly in an open configuration when uncon 
strained. The jaw members 72 may be formed from biocom 
patible resilient materials such as initinol, stainless steel and 
plastics. Needle shaft 74 is slidably disposed within lumen 66 
and preferably slidably disposed shaft lumen 69. Needle shaft 
74 includes a needle tip 76 and a needle lumen 78. Needle 
lumen 78 extends from the proximal end of needle shaft 74 to 
needle tip 76. FIG. 7A illustrates jaw members 72 in a first 
state in which jaw members 72 are closed and constrained by 
the walls of sheath member 62 and disposed within lumen 66. 
Additionally, needle tip 78 of needle shaft 74 is in a first 
configuration in which needle tip 78 is positioned proximal to 
jaw members 72. By moving the elongate shaft member 68 
distally relative to sheath member 62, jaw members 72 are 
caused to exit the lumen 66 at distal end 64 of sheath 62. FIG. 
7B shows jaw members 72 in a second state in which in which 
the jaw members 72 are open and unconstrained after exiting 
lumen 66. FIG.7C illustrates needle tip 78 of needle shaft 74 
positioned in a second configuration in which needle tip 78 is 
positioned between jaw members 72. 
FIGS. 8A through 8E illustrates the operation of safe 
access needle injection instrument 60. Insertion section 6 of 
endoscope 2 is passed through a natural orifice inapatient and 
positioned at a location in the digestive tract in which to 
perform a submucosal procedure. Safe access needle injec 
tion instrument 60 is deployed through the working channel 4 
of endoscope 2. As depicted in FIG. 8A the distal potion of 
safe access needle injection instrument 60 is positioned 
within the digestive tract adjacent mucosal layer 46. Beneath 
the mucosal layer are the Submucosal layer 48 and the mus 
cular layer 50. Jaw members 72 are positioned on mucosal 
layer 46. Needle tip. 76 is located in a first position proximal 
to jaw members 72. Distal movement of sheath member 62 
relative to the elongate shaft member causes the jaw members 
72 to become partially constrained in lumen 66 and move 
towards a closed position thereby grasping the tissue of the 
digestive tract as shown in FIG. 8B. FIG. 8C is a cross-section 
view along section line 8C-8C in FIG. 8B showing the tissue 
engaged by jaw members 72. The mucosal layer 46 and 
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submucosal layer 48 are firmly held between jaw members 
72. Needle tip. 76 is moved from the first position proximal to 
jaw members 72 to the second position betweenjaw members 
72 thereby piercing the mucosal layer 46 and entering the 
submucosal layer 48 as shown in FIG.8D. FIG. 8E illustrates 
the delivery of fluid through needle shaft 74 exiting needle tip 
76 into the submucosal layer 48 thereby elevating mucosal 
layer 46 to form a submucosal bleb. The fluid used to create 
the bleb may be of any type suitable for the environment such 
as Solutions containing saline, hypertonic Solutions of saline 
epinephrine, sodium hyaluronate, poly-N-acetylglu 
cosamine, Sodium chondroitin Sulfate, chitosans or other bio 
compatible mucopolysaccharides. 
FIGS. 9 and 10 show a variation of safe access needle 
injection instrument 60 in which jaw members 72 are coupled 
to distal end 70 of elongate shaft member 68 by a collar 
member 80. Collar member 80 is joined to distal end 70 by 
Suitable means known in the art Such as gluing, soldering or 
welding. Jaw members 72 are connected to collar member 80 
in a way that allows the jaw members 72 to rotate relative to 
distal end 70 of elongate shaft member 68. The rotational 
movement of jaw members 72 allows the physician to quickly 
orient the jaw members 72 relative the surface of the tissue 
surface within the digestive tract. Although jaw members 72 
are connected to collar member 80, proximal movement of 
elongate shaft member 68 relative to sheath member 62 will 
causejaw members 72 to move to a closed position within the 
lumen 66 of sheath member 62. Collar member 80 includes an 
aperture through which needle shaft 74 may extend in a 
slidable fashion. Additionally, jaw members 72 include a 
tissue grasping Surface 82 that facilitates the engagement of 
tissue within the digestive tract. While tissue grasping surface 
82 is shown in the form of a serrated surface, it may also take 
the form of a knurled Surface or a Surface containing multiple 
protrusions or dimples to improve the tissue grasping ability 
of jaw members 72. Tissue grasping Surface 82 may be inte 
grally formed with jaw members 72 or bonded to jaw mem 
bers 72. Tissue grasping surface 82 may beformed of metals, 
polymers or composite materials. 
FIGS. 11A and 11B show a safe access dissection system 
100 of the present invention that includes a safe access needle 
injection instrument 10 and an injectable dissection material 
102. The injectable dissection material 102 takes the form of 
a solution capable of dissolving the Submucosal connective 
tissue. An example of this type of dissolving Solution is 
sodium 2-mercaptoethanesulfanate (MESNA). Additional 
Substances which may dissolve the Submucosal connective 
tissue include acids and enzymes Such as a peptase enzyme 
Solution, protease/collagenase, papain, chymotrypsin and 
acetylcysteine. A safe access needle injection instrument 10 is 
used to create a safety bleb beneath the mucosal layer 46 in 
the digestive tract of a mammal. Once the safety bleb is 
formed, the injectable dissection material 102 may be deliv 
ered through needle tip 40 into the submucosal layer 48 as 
shown in FIG. 11A. Injectable dissection material 102 begins 
to breakdown the stretched submucosal connective tissue 52. 
Under the force imparted by the distention of the bleb, the 
Submucosal connective tissue 52 breaks, thereby causing the 
mucosal layer 46 to be come detached from muscular layer 50 
in bleb region as shown in FIG. 11B. 
FIGS. 12A and 12B show a safe access dissection system 
104 of the present invention that includes a safe access needle 
injection instrument 10 and an injectable dissection material 
106. The injectable dissection material 106 takes the form of 
a semisolid gelatin capable of mechanically breaking the 
Submucosal connective tissue 52. The semisolid gelatin may 













tins. Generally, these gelatins are in a powdered form and 
mixed with warm water. Upon cooling, the gelatin forms a 
semisolid consistency with physical cross links. The gelatin 
material is preferably formed within the barrel of a pressur 
izable syringe since aspiration of this material is difficult. A 
safe access needle injection instrument 10 is used to create a 
safety bleb beneath the mucosal layer 46 in the digestive tract 
of a mammal. Once the safety bleb is formed, the injectable 
dissection material 106 may be delivered through needle tip 
40 into the submucosal layer 48 as shown in FIG. 12A. The 
mass and semisolid nature of the injectable dissection mate 
rial 106 begins to apply force to the stretched submucosal 
connective tissue 52, unlike a saline solution which only 
permeates the submucosal layer 48. Under the force imparted 
by the increased volume due to the introduction of the inject 
able dissection material 106, the submucosal connective tis 
sue 52 breaks, thereby causing the mucosal layer 46 to be 
come detached from muscular layer 50 in bleb region as 
shown in FIG. 12B. Alternatively, the injectable dissection 
material 106 may also take the form of injectable solutions 
which Solidify upon entering the Submucosal space. Solu 
tions which solidify after injection into the Submucosal space 
may be thermo sensitive polymer Solutions such as Pluronic 
127. Additional injectable solidifying solutions include 
monomer and polymer Solutions like hydrogels and 
cyanoacrylates which polymerize or crosslink upon contact 
with tissue or added chemical agents. 
FIGS. 13A and 13B show a safe access dissection system 
108 of the present invention that includes a safe access needle 
injection instrument 10 and an injectable dissection material 
110. The injectable dissection material 110 takes the form of 
gelled microspheres dispersed in a solution capable of 
mechanically breaking the Submucosal connective tissue 52. 
The microspheres may be formed using biocompatible natu 
ral materials such as collagen and alginates or synthetic mate 
rials like polyvinylalcohol (PVA), polyvinylpyrolidone 
(PVP) and acrylate polymers. A safe access needle injection 
instrument 10 is used to create a safety bleb beneath the 
mucosal layer 46 in the digestive tract of a mammal. Once the 
safety bleb is formed, the injectable dissection material 110 
may be delivered through needle tip 40 into the submucosal 
layer 48 as shown in FIG. 13A. The mass and solid nature of 
the injectable dissection material 110 begins to apply force to 
the stretched submucosal connective tissue 52, unlike a saline 
solution which only permeates the submucosal layer 48. 
Under the force imparted by the increased volume due to the 
introduction of the injectable dissection material 110, the 
Submucosal connective tissue 52 breaks, thereby causing the 
mucosal layer 46 to become detached from muscular layer 50 
in bleb region as shown in FIG. 13B. 
FIG. 14 illustrates a submucosal tunneling instrument 120 
for performing a submucosal medical procedure of the 
present invention. The Submucosal tunneling instrument 120 
includes a catheter 122 having proximal and distal ends and a 
balloon member 124 located adjacent the distal end. The 
proximal end of catheter 122 is attached to connector tubing 
126 to access inflation port 128. Valve assembly 130 provides 
a seal for fluid introduced into inflation port 128. Tether slide 
132 is slidably positioned on handle body 134. Handle body 
134 includes distance markers 136 to gauge the movement of 
tether slide 132. 
A cross sectioned view of the distal end of the submucosal 
tunneling instrument 120 is shown in more detail in FIG. 15. 
Catheter 122 has a distal end 138 and a lumen 123. Located 
within lumen 123 is balloon member 124. The balloon mem 
ber 124 is preferably noncompliant of the type generally 
known in the art, however, balloon member 124 may be of the 
US 8.491472 B2 
15 
compliant or semi-compliant type. The balloon member 124 
may be formed from biocompatible polymer types such as 
olefins, elastomers, thermoplastic elastomers, vinyls, polya 
mides, polyimides, polyesters, fluropolymers, copolymers 
and blends of any of the aforementioned. The proximal end 
140 of balloon member 124 is attached to the distal end 138 of 
catheter 122. The distal end 142 of balloon member 124 is 
positioned within the lumen 123 in an everted configuration. 
A tether member 144 is connected to the distal end 142 of 
balloon member 124. Tether member 144 is flexible and 
preferably takes the form of a filament, as shown, however 
tether member 144 may take the form of a tube. The proximal 
end of tether member 144 is connected to tether slide 132 
through valve assembly 130. Tether member 144 aids in ini 
tially positioning balloon member 124 within the lumen 123 
of catheter 122. While the aforementioned embodiment of the 
Submucosal tunneling instrument include an expandable 
member which preferably takes the form of an inflatable 
balloon, other devices may be suitable for essentially per 
forming the same function. For instance as depicted in an 
alternate embodiment shown in FIG. 15B, the expandable 
member 124 may take the form of an expandable elongate 
braid, mesh or tubular framework in which the proximal end 
of the expandable member is connected to the distal end of the 
catheter and the distal end of the expandable member is 
everted and positioned within the lumen of the catheter. A 
stiffened tether member 144 located within the lumen of the 
catheter 122 may be used as a pusher to push the expandable 
elongate member from the lumen of the catheterinessentially 
the same way that the balloon expands from the lumen of the 
catheter. The expandable elongate braid may be formed from 
resilient materials such as nitinol, spring steels, vitreloy, as 
well as polymers and composites. The expandable member 
may take comprise individual wires to form a braid or mesh 
configuration. Alternatively the expandable member may be 
laser cut from a tube forming a tubular framework. Preferably 
the expanded diameter is larger than the outer diameter of the 
catheter. 
FIGS. 16A through 16C illustrate various stages of deploy 
ment of balloon member 124 from the lumen 123 of catheter 
122. To deploy balloon member 124 a fluid filled syringe or 
other source is connected to inflation port 128. As pressurized 
fluid enters the lumen 123 of catheter 122, the proximal end of 
balloon member 124 exits the lumen expands. Balloon mem 
ber 124 has an expanded diameter range of about 1 mm to 
about 30 mm and is preferably in the range of 2 mm to 20 mm. 
The length of balloon member 124 is a long as necessary to 
performa desired submucosal medical procedure. This length 
can be in the range of 5 mm to 50 cm and preferably in the 
range of 7 mm to about 10 cm. As balloon member 124 
expands it extends in a linear fashion moving the distal end 
142 of balloon member 124 towards the distal end 138 of 
catheter 122. As long as pressurized fluid is applied to cath 
eter lumen 123, balloon 124 will extend to its full length. 
Alternatively, since the distal end 142 of balloon 124 is con 
nected to tether member 144, the amount of linear extension 
balloon 124 takes may be controlled by the tether slide 132 to 
define an extension length shorter than the full length of the 
balloon. 
FIG. 17 illustrates a submucosal tunneling instrument 150 
for performing a submucosal medical procedure of the 
present invention. The submucosal tunneling instrument 150 
includes a catheter 152 having proximal and distal ends and a 
balloon member 154 located adjacent the distal end. Posi 
tioned on the exterior of catheter 152 adjacent the distal end is 
a series of markers 156. These markers may be visible under 














visible under fluoroscopy. Adjacent the proximal end of cath 
eter 152 is an auxiliary device port 158. The proximal end of 
catheter 152 is attached to connector tubing 160 to access 
inflation port 162. Valve assembly 164 provides a seal for 
fluid introduced into inflation port 162. Tether slide 166 is 
slidably positioned on handle body 168. Handle body 168 
includes distance markers 170 to gauge the movement of 
tether slide 166. 
A cross sectioned view of the distal end of the submucosal 
tunneling instrument 150 is shown in more detail in FIG. 18. 
Catheter 152 has a distal end 172 and a first lumen 174. 
Located within first lumen 174 is balloon member 154. The 
balloon member 154 is preferably non-compliant of the type 
generally known in the art, however, balloon member 154 
may be of the compliant or semi-compliant type. The balloon 
member 154 may be formed from biocompatible polymer 
types such as olefins, elastomers, thermoplastic elastomers, 
vinyls, polyamides, polyimides, polyesters, fluropolymers, 
copolymers and blends of any of the aforementioned. The 
proximal end 176 of balloon member 154 is attached to the 
distal end 172 of catheter 152. The distal end 178 of balloon 
member 154 is positioned within the first lumen 174 in an 
everted configuration. A tether member 180 is connected to 
the distal end 178 ofballoon member 154. Tether member 180 
is flexible and preferably takes the form of a filament, as 
shown, however tether member 180 may take the form of a 
tube. The proximal end of tether member 180 is connected to 
tether slide 166 through valve assembly 164. Tether member 
180 aids in initially positioning balloon member 154 within 
the first lumen 174 of catheter 152. Catheter 152 has a second 
lumen 182 that extends from auxiliary device port 158 to 
distalend 184. Distalend 184 is located proximal to distalend 
172 of catheter 152. Slidably disposed within second lumen 
182 is a needle knife 184 that has a knife tip 188. Needle knife 
184 is preferably of the endoscopic electrosurgical type how 
ever any form of incision device that may be operated to form 
an incision in tissue such as mechanical cutters, water jets or 
lasers may be suitable. 
FIGS. 19A through 19C illustrate a submucosal tunneling 
instrument 200, according to another embodiment of the 
present invention. Catheter 202 has a distal end 204 which is 
connected to balloon member 206. The proximal end 208 of 
balloon 206 is connected to distal end 204 of catheter 202. 
Balloon member 206 is rolled into a spiral configuration in 
which the distal end 210 is located in the center of the spiral. 
As the lumen of catheter 202 which is connected to balloon 
member 206 is pressurized, balloon member 206 inflates. The 
inflation of balloon member 206 causes the balloon to unroll 
from a spiral configuration extending linearly. The balloon 
member 206 may be thermally treated to retain the spiral 
configuration for delivery through the working channel of an 
endoscope. Alternatively the balloon member 206 may incor 
porate a spiral shaped member 212 attached the wall of bal 
loon member 206 as shown in FIGS. 20A and 20B. The spiral 
shaped member may be formed from a resilient filament as 
shown in an outstretched configuration in FIG. 20A. The 
spiral shaped member being formed of a resilient filament and 
incorporated into the wall of the balloon preferably takes its 
spiral shape and in doing so forms the balloon member into a 
spiral shape as shown in FIG.20B. 
In order to perform a Submucosal medical procedure, the 
target area in the digestive tract must be prepared to gain 
access to the submucosal space. FIGS. 21A and 21B illustrate 
a desired region 220 of the digestive tract of a mammal. A safe 
access needle injection instrument according to any of the 
embodiments previously described may be used to form a 
safety bleb 222 beneath the mucosal layer 46. The safety bleb 
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contains the Submucosal connective tissue 52 generally in a 
stretched condition attached to both the mucosal layer 46 and 
the muscular layer 50. As shown in FIGS. 22A and 22B, an 
endoscopic incision tool 224 is positioned adjacent to the 
safety bleb 222. An incision tool tip 226 of the endoscopic 
incision tool 224 is used to create a small mucosal opening 
228 in the mucosal layer 46 of the safety bleb. The elevated 
mucosal layer 46 reduces the likelihood that the incision tool 
tip 226 will damage the underlying muscular layer 50. FIGS. 
23A through 24D illustrate the introduction and operation of 
a submucosal tunneling instrument into Submucosal layer 48. 
The distal end 138 of the submucosal tunneling instrument 
120 is positioned through the mucosal opening 228. Once the 
proximal end 140 of balloon 124 is through the mucosal 
opening 228 the Submucosal tunneling instrument 120 may 
be operated. By delivering pressurized fluid through the 
lumen of catheter 122, the proximal end 140 of balloon 124 
inflates to its expanded diameter as depicted in FIG. 23C. 
Generally the expanded diameter of the proximal end 140 of 
balloon 124 is larger than the diameter of the mucosal open 
ing 228. The larger diameter prevents balloon 124 from push 
ing the distal end 138 of catheter 122 backwards out of the 
Submucosal layer 48through mucosal opening 228. As shown 
in FIG. 23D, further inflation extends balloon 124 in a linear 
fashion within the Submucosal layer 48 causing the Submu 
cosal connective tissue 52 to break in regions adjacent to the 
balloon. The balloon 124 can only expand by increasing the 
volume of the surrounding area between the mucosal layer 46 
and the muscular layer 50. The application of force during 
expansion of balloon 124 is concentrated on the Submucosal 
connective tissue 52, thereby causing the Submucosal con 
nective tissue 52 to break, whereas the force applied to the 
mucosal layer 46 or the muscular layer 50 by balloon 124 is 
diluted over a larger portion of balloon 124. The force 
required to break the submucosal connective tissue 52 as 
applied by balloon 124 is less than the force required to 
perforate the mucosal layer 46 or muscular layer 50 by bal 
loon 124 thereby minimizing trauma to Surrounding tissue. 
FIG. 24A illustrates a perspective view of region 220 in the 
digestive tract having a submucosal tunnel 230 formed by 
submucosal tunneling instrument 120. As shown in FIG.24B, 
balloon 124 is fully expanded and generally occupies the 
majority of the space of submucosal tunnel 230. Balloon 124 
is then deflated by applying a negative pressure to catheter 
122 and retracting tether member 144. The distal end 138 of 
catheter 122 is then removed from mucosal opening 228, 
leaving submucosal tunnel 230 generally deflated. The sub 
mucosal connective tissue 52 within the tunnel is broken. For 
Some submucosal medical procedures the Submucosal tunnel 
230 may provide suitable access to the muscular wall or the 
placement of an implant device. However to perform other 
Submucosal medical procedures an area larger than the Sub 
mucosal tunnel 230 may be desired. 
FIGS. 25A through 25D illustrate the formation of an area 
larger than a submucosal tunnel for performing a Submucosal 
medical procedure according to an embodiment of the present 
invention. A region 220 in the digestive tract is prepared by 
forming a submucosal tunnel 230. A submucosal dissection 
instrument 240 having a catheter 242 is positioned through 
mucosal opening 228 into Submucosal tunnel 230. Located on 
catheter 242 are markers 244 that indicate the insertion depth 
of catheter distal end 246 within submucosal tunnel 230. The 
Submucosal dissection instrument 240 is in a proper position 
for operation when balloon member 248 including distal end 
250 and proximal end 252 are sufficiently located within 
submucosal tunnel 230, as shown in FIG.25B. As pressurized 














communication with balloon member 248, balloon member 
248 inflates. During the expansion of balloon member 248, 
the submucosal connective tissue 52 is broken in the area of 
the expanded balloon member 248 and the mucosal layer 46 
is elevated. The elevated mucosal layer 46 forms a large 
mucosal dissected area 260. After full expansion the balloon 
member 248 may be deflated and submucosal dissecting 
instrument 240 removed from the large mucosal dissected 
area 260. The dissected region beneath mucosal layer 46 has 
transformed in geometry from a high aspect ratio tunnel to a 
low aspect ratio chamber Suitable for performing some Sub 
mucosal medical procedures. 
Aforementioned descriptions of Submucosal tunneling 
instruments and Submucosal dissecting instruments have 
shown separate instruments to create a Submucosal tunnel or 
large mucosal dissected area however the two types of instru 
ments may be combined to form a submucosal tunneling 
dissecting instrument 270 as illustrated in FIG. 26. The sub 
mucosal tunneling dissecting instrument 270 includes a dis 
section catheter 272 having a distal end 274 and a dissection 
balloon 276 having an expanded dissection balloon 276a 
configuration. The dissection balloon 276 can be compliant of 
the type generally known in the art or dissection balloon 276 
may be of the compliant or semi-compliant type. The dissec 
tion balloon 276 may beformed from biocompatible polymer 
types such as olefins, elastomers, thermoplastic elastomers, 
vinyls, polyamides, polyimides, polyesters, fluropolymers, 
copolymers and blends of any of the aforementioned. The 
dissection catheter 272 has insertion markers 278 positioned 
along its shaft. The proximal end of dissection catheter 272 
includes both an inflation port 280 that is in fluid communi 
cation with dissection balloon 276, and a valve assembly 282. 
Tunneling catheter 284 is slidably disposed through valve 
assembly 282 extending within alumen of dissection catheter 
272. The tunneling catheter distal end 286 may extend beyond 
the dissection catheter distal end 274. Tunneling catheter 284 
includes an inflation port 288 and valve assembly 290. A 
tether slide member 292 is slidably disposed on handle body 
294 with distance markers 296. FIG. 27 illustrates a detailed 
cross section of the distal portion of the Submucosal tunneling 
dissecting instrument 270. The distal end 298 and proximal 
end 300 of dissection balloon 276 are connected to the exte 
rior of dissection catheter 272. Inflation lumen 302 connects 
inflation port 280 with the interior of dissection balloon 276 
through inflation aperture 304. Tunneling catheter 284 is slid 
ably disposed within the lumen 306 of dissection catheter 
272. Positioned within the lumen 308 of tunneling catheter 
284 there is an everted expandable tunneling balloon 310. The 
tunneling balloon 310 is preferably non-compliant of the type 
generally known in the art, however, tunneling balloon 310 
may be of the compliant or semi-compliant type. The tunnel 
ing balloon 310 may be formed from biocompatible polymer 
types such as olefins, elastomers, thermoplastic elastomers, 
vinyls, polyamides, polyimides, polyesters, fluropolymers, 
copolymers and blends of any of the aforementioned. The 
distal end of tunneling balloon 310 is connected to a tether 
member 312 which has a proximal end that is connected to 
tether slide 292. 
The operation of the Submucosal tunneling dissecting 
instrument 270 to form a submucosal tunnel and large 
mucosal dissected area is similar to the operation of the sepa 
rate instruments. In general, the distal end 286 of tunneling 
catheter 284 is positioned through a mucosal opening formed 
in a safety bleb. The tunneling catheter 284 is pressurized 
with fluid to linearly expand tunneling balloon 310. Once a 
submucosal tunnel has been formed tunneling balloon 310 
may be deflated and dissection catheter 272 may be advanced 
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through the mucosal opening into the Submucosal tunnel. The 
markers 278 may be used to determine the depth in which the 
dissection catheter 272 has been advanced into the submu 
cosal tunnel. Once the dissection catheter 272 has been prop 
erly positioned within the Submucosal tunnel it may be oper 
ated. By applying pressurized fluid to inflation port 280, 
dissection balloon 276 is dilated to an expanded dissection 
balloon 276a configuration. During the expansion a large 
mucosal dissected area is created which is accessible for 
performing a Subsequent Submucosal medical procedure. 
Another embodiment of the present invention includes a 
Submucosal implant device for diagnosing and treating dis 
orders of the body. The submucosal implant device may be a 
passive or active device. Active devices may include self 
contained electronics for controlling the device, as well as an 
internal power Supply. Alternatively, the active devices may 
be controlled externally by telemetry. A passive submucosal 
implant device may take the form of a drug delivery depot in 
which a therapeutic agent within the depot elutes from the 
depot according to a predetermined elution profile. An active 
Submucosal implant device may take the form of a drug 
delivery device that incorporates a self contained diagnostic 
system to determine the appropriate delivery time and dosage 
of a therapeutic agent to be administered. The passive or 
active submucosal implant device which takes the form of a 
drug delivery device may include a port positioned through 
the mucosal layer to allow endoscopic refilling of the drug 
delivery device with therapeutic agents. Submucosal implant 
devices that are drug delivery devices have the ability to 
deliver therapeutic agents directly to the portal circulation. 
Many different types of therapeutic agents may be delivered 
Such as pharmaceuticals, hormones, growth factors and other 
biological compounds. Some typical therapeutic agents for 
use in a Submucosal implant device of the present invention 
include dromostanolone, dromostanolone propionate, chlor 
madinone, chlormadinone acetate, dimethisterone, ethister 
one, hydroxyprogesterone, norgestomet and other nor 
steroids Such as norethindrone, norgesterone, northylodrel, 
norgestrel, noregestrienone, and norgestoniel; melengestrol 
acetate, estradiol. 17O-acetoxy-113-methyl-19-norpregn-4- 
ene-320-dione, 3(3-oxo-113, 13 B-dialkl-17 3-hydroxygon 
4-en-17C.-yl)propionic acid-lactone, 3-(3-oxo-113methyl 
17B-hydroxyestr-4-en-17C.-yl)-propionic acid lactone, 
11, 13 B-dialkyl-17 lower alkyl-17 lower alkyl-gon-4-en-3 
one, 19-morpregn-4-ene-320-dione, oxytocin, vasopressin, 
adrenocorticotropic hormone, epidermal growth factor, pro 
lactin, luliberin, luteinizing hormone releasing factor, growth 
hormone releasing factor, insulin, Somatostatin, glucagon, 
interferon, gastrin, tetragastrin, pentagastrin, urogestrone, 
secretin, calcitonin, enkephalins, endorphins, angiotensins, 
renin, bradykinin, bacitracins, polymyxins, colistins, tyroci 
din, gramicidines, synthetic analogues, modifications and 
pharmaceutically-active fragments of polypeptides, mono 
clonal antibodies, soluble vaccines. Somatropin, Somatotro 
pin, cosyntropin, gonadotropins, chorionic gonadotropin, 
thyrotropin releasing hormone, thyroid stimulating hormone, 
pancreozymin and enkephalins. 
By delivering therapeutics Submucosally, Some problems, 
Such as digestion, which prevent the oral delivery of some 
therapeutic compounds, may be overcome. One Such thera 
peutic compound that may be delivered through the Submu 
cosal implant device that cannot be administered orally is the 
hormone cholecytokinin (CCK). This hormone has been 
shown to be instrumental in triggering the brain to tell the 
body to stop eating by inducing Satiety. As an appetite Sup 













An active submucosal implant device may take the form of 
a drug delivery device in which electrical signals are received 
from the contraction of the muscular wall of a mammal to 
deliver a specified amount of therapeutic agent. The Submu 
cosal implant may include an anchor member in which to 
secure the implant to the muscular wall beneath the mucosal 
layer. This anchor may be integrally formed with an electrode 
for receiving electrical signals from the wall. Multiple sub 
mucosal implant devices may be deposited at various loca 
tions along the stomach wall. 
FIG. 28 shows a portion 409 of the digestive system in 
which a submucosal implant device 410 is placed within the 
wall of the stomach. FIGS. 29A through 29C illustrate a 
sequence for deploying a submucosal implant device accord 
ing to an embodiment of the present invention. A submucosal 
tunnel 230 or a large mucosal dissected area is formed in a 
portion of the digestive tract. The insertion section 6 of an 
endoscope is positioned through an enlarged mucosal open 
ing 228 into the Submucosal space. The Submucosal implant 
device 410 and an implant deployment device 412 are 
inserted through the mucosal opening 228 and preferably 
through a working channel of the endoscope into the Submu 
cosal space. Implant deployment device 412 is used to posi 
tion submucosal implant device 410 within the submucosal 
space. Submucosal implant device 410 preferably takes the 
form of a drug delivery depot. The submucosal implant 
device may be in the form of a hydrogel, gel matrix, Soluble 
wax or configurations commonly used in transdermal drug 
delivery devices. Submucosal implant device 410 is shown in 
a first configuration for delivery into the Submucosal space 
and a second configuration for deployment adjacent muscular 
layer 50. Implant deployment device 412 is operated to move 
submucosal implant device 410 from its first configuration to 
the second configuration. Implant deployment device 412 
then releases submucosal implant device 410 into the submu 
cosal space. The implant deployment device 412 and endo 
Scope insertion section 6 are then removed from the Submu 
cosal space and the mucosal opening 228 is then closed using 
clips, Suture or other closure techniques. 
FIGS. 30A through 30C illustrate a submucosal implant 
device and sequence for deploying the device according to 
another embodiment of the present invention. A submucosal 
tunnel 230 or a large mucosal dissected area is formed in a 
portion of the digestive tract. The insertion section 6 of an 
endoscope is positioned through an enlarged mucosal open 
ing 228 into the Submucosal space. The Submucosal implant 
device 414 and an implant deployment device 416 are 
inserted through the mucosal opening 228 and preferably 
through a working channel of the endoscope into the Submu 
cosal space. The relative sizes shown are for clarity; in prac 
tice, implant device be relatively smaller to permit passage 
through the working channel Implant deployment device 416 
is used to position submucosal implant device 414 within the 
Submucosal space. Submucosal implant device 414 also 
includes an anchor member 418 and a tether member 420. 
Anchor member 418 is adapted to be affixed to the muscular 
layer 50 and retain the submucosal implant device 414 in 
position by tether member 420. Submucosal implant device 
414 preferably takes the form of a drug delivery device. In 
addition to performing anchoring and tethering functions, 
anchor member 418 and tether member 420 also function as 
an electrode and electrical conductor respectively. Electrical 
signals may be received by the Submucosal implant device 
414 from muscular layer 50 via anchor member 418 and 
tether member 420. Implant deployment device 416 then 
releases Submucosal implant device 414 into the Submucosal 
space. The implant deployment device 416 and endoscope 
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insertion section 6 are then removed from the submucosal 
space and the mucosal opening 228 is then closed using 
closure clips 422 with a clip applier 424. Other closure tech 
niques and devices such as Sutures, staples and adhesives may 
also be suitable for closing mucosal opening 228. 
FIGS. 31A through 31F illustrate another submucosal 
implant device and a sequence for deploying the device 
according to another embodiment of the present invention. A 
Submucosal tunnel 230 or a large mucosal dissected area is 
formed in a portion of the digestive tract. The insertion sec 
tion 6 of an endoscope is positioned through an enlarged 
mucosal opening 228 into the Submucosal space. The Submu 
cosal implant device 430 and an implant deployment device 
432 are inserted through the mucosal opening 228 and pref 
erably through a working channel of the endoscope into the 
Submucosal space. The relative sizes shown are for clarity; in 
practice, implant device be relatively smaller to permit pas 
sage through the working channel. Implant deployment 
device 432 is used to position submucosal implant device 430 
within the Submucosal space. Submucosal implant device 
430 includes a therapeutic agent delivery port 434, an anchor 
member 436 and a tether member 438. Anchor member 436 is 
adapted to be affixed to the muscular layer 50 and retain the 
submucosal implant device 430 in position by tether member 
438. Submucosal implant device 430 preferably takes the 
form of a therapeutic drug delivery device incorporating an 
internal drug reservoir. In addition to performing anchoring 
and tethering functions, anchor member 436 and tether mem 
ber 438 also function as an electrode and electrical conductor 
respectively. Electrical signals may be sent and received by 
the submucosal implant device 430 to and from muscular 
layer 50 via anchor member 436 and tether member 438. The 
electrical signals may be used by the submucosal implant 
device 430 to initiate or terminate delivery of a therapeutic 
agent through delivery ports 434. Submucosal implant device 
430 also includes a refill tube 440 connected to a mucosal port 
442. Mucosal port 442 contains a valve assembly that can 
restrict fluid access to refill tube 440. Implant deployment 
device 432 positions the refill tube 440 within the submucosal 
space while the mucosal port 442 is positioned through 
mucosal layer 46. Implant deployment device 432 then 
releases submucosal implant device 430 into the submucosal 
space. The implant deployment device 432 and endoscope 
insertion section 6 are then removed from the submucosal 
space and the mucosal opening 228 is then closed using 
closure clips 422 with a clip applier 424. Other closure tech 
niques and devices such as Sutures, staples and adhesives may 
also be Suitable for closing mucosal opening 228. The endo 
scope and related materials may then be removed from the 
patient. At a later time period, after the reservoir of submu 
cosal implant device 430 has been depleted the physician may 
return endocopically to the site of the implant and use a 
refilling instrument 444 having a tip 446 that engages the 
mucosal port 442 to deliver more drugs to refill the reservoir. 
Novel instruments, systems and methods have been dis 
closed to perform Submucosal medical procedures in the 
digestive tract of a mammal. Although preferred embodi 
ments of the invention have been described, it should be 
understood that various modifications including the Substitu 
tion of elements or components which perform Substantially 
the same function in the same way to achieve Substantially the 
same result may be made by those skilled in the art without 
departing from the scope of the claims which follow. 
What is claimed is: 
1. A submucosal implant system comprising: 
a) a safe access needle injection means having a needle 
member adapted to pierce a mucosal tissue and deliver 













b) a Submucosal tunneling means including an elongate 
tubular member having proximal and distal ends and a 
lumen extending therethrough and an expandable mem 
ber having first and second ends wherein said first end of 
said expandable member is attached to said distal end of 
said tubular member and said second end of said expand 
able member is everted and positioned within said lumen 
of said tubular member, 
wherein said distal end of said elongate tubular member is 
adapted to enter an opening through the mucosal layer 
and into the Submucosal layer of a mammal; 
c) a Submucosal dissection means including an elongate 
tubular member having proximal and distal sections and 
an expandable member disposed at said distal section of 
said tubular member; and, 
d) an implantable therapeutic agent delivery device. 
2. A submucosal implant system according to claim 1 
wherein said safe access needle injection means comprises: 
an elongate tubular member having proximal and distal 
ends and a lumen extending therethrough; 
a tissue holding member positioned adjacent the distal end 
of said elongate tubular member and is adapted to 
engage a desired region of a mucosal layer, and, 
said needle member having a lumen wherein said needle 
member is slidably disposed within the lumen of said 
elongate tubular member and adapted to pierce a desired 
region of the mucosal layer engaged by said tissue hold 
ing member and enter the Submucosal layer Such that 
delivery of a fluid through the lumen of said needle 
member enters said submucosal layer to thereby elevate 
said desired region of the mucosal layer. 
3. A submucosal implant system according to claim 1 
wherein said Submucosal dissecting means comprises an 
elongate tubular member having proximal and distal sections 
and an expandable member disposed at the distal section of 
said tubular member. 
4. A submucosal implant system according to claim 1 
wherein said Submucosal tunneling means and said Submu 
cosal dissecting means are integrally formed. 
5. A submucosal implant system according to claim 1 
wherein said implantable therapeutic agent delivery device 
includes an anchor. 
6. A submucosal implant system, comprising: 
a) a safe access needle injection means having a needle 
member adapted to pierce mucosal tissue and deliver 
fluid to the submucosal layer; 
b) a Submucosal tunneling means including an elongate 
tubular member having proximal and distal ends and a 
lumen extending therethrough, and an expandable mem 
ber having first and second ends wherein said first end of 
said expandable member is attached to said distal end of 
said tubular member and said second end of said expand 
able member is everted and positioned within said lumen 
of the tubular member, 
wherein the distal end of said elongate tubular member is 
adapted to enter an opening through the mucosal layer 
and into the Submucosal layer of a mammal; 
c) a Submucosal dissection means including an elongate 
tubular member having proximal and distal sections and 
an expandable member disposed at the distal section of 
said tubular member; and, 
d) an implantable drug delivery device. 
7. A submucosal implant system according to claim 6 
wherein said safe access needle injection means comprises: 
an elongate tubular member having proximal and distal 
ends and a lumen extending therethrough; 
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a tissue holding member positioned adjacent the distal end 
of said elongate tubular member and is adapted to 
engage a desired region of a mucosal layer, and, 
said needle member having a lumen wherein said needle 
member is slidably disposed within the lumen of said 
elongate tubular member and adapted to pierce a desired 
region of the mucosal layer engaged by said tissue hold 
ing member and enter the Submucosal layer Such that 
delivery of a fluid through the lumen of said needle 
member enters said submucosal layer to thereby elevate 
said desired region of the mucosal layer. 
8. A submucosal implant system according to claim 6 
wherein said implantable drug delivery device includes an 
anchor. 
9. A submucosal implant system, comprising: 
a) a safe access needle injection instrument having a needle 
member adapted to pierce mucosal tissue and deliver 
fluid to the submucosal layer; 
b) a Submucosal tunneling device having an expandable, 
evertable distal end; 
c) a Submucosal dissection device having an expandable 
distal end, 
wherein each of said tunneling device and said dissec 
tion device has a closed distal end; and 
d) an implantable drug delivery device. 
10. A submucosal implant system according to claim 9 
wherein said distal end of said tunneling device is longitudi 
nally expanding, and said distal end of said dissection device 





11. A submucosal implant system according to claim 9 
wherein said implantable drug delivery device includes an 
anchor. 
12. A submucosal implant system according to claim 11 
wherein said implantable drug delivery device includes an 
anchor. 
13. A Submucosal implant system, comprising: 
a) a safe access needle injection means having a needle 
member adapted to pierce mucosal tissue and deliver 
fluid to the submucosal layer; 
b) a Submucosal tunneling means having a distal end with 
a longitudinally expandable, evertable tip; 
c) a Submucosal dissection means including an elongate 
tubular member having proximal and distal sections, an 
expandable member disposed at said distal section of 
said tubular member, and an open distal end, 
wherein said expandable tip of said tunneling means is 
longitudinally displaceable through said open distal 
end and relative to said expandable member of said 
dissection means; and 
d) an implantable drug delivery device. 
14. A submucosal implant system according to claim 13, 
wherein said Submucosal tunneling means and said Submu 
cosal dissecting means are integrally formed. 
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